Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine, University Hospital of Geneva (HUG), Rue Gabrielle-Perret-Gentil 4, 1211, Geneva 14, Switzerland.
Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva, Geneva, Switzerland.
Clin Pharmacokinet. 2021 Dec;60(12):1537-1555. doi: 10.1007/s40262-021-01064-4. Epub 2021 Aug 31.
Cytochromes P450 (CYP) are the major enzymes involved in hepatic metabolism of drugs. Personalization of treatment in pediatrics is a major challenge, as it must not only take into account genetic, environmental, and physiological factors but also ontogeny. Published data in adults show that inflammation had an isoform-specific impact on CYP activities and we aimed to evaluate this impact in the pediatric population.
Articles listed in PubMed through 7 January, 2021 that studied the impact of inflammation on CYP activities in pediatrics were included in this systematic review. Sources of inflammation, victim drugs (CYP involved), effect of drug-disease interactions, number and age of subjects, and study design were extracted.
Twenty-seven studies and case reports were included. The impact of inflammation on CYP activities appeared to be age dependent and isoform-specific, with some drug-disease interactions having significant pharmacokinetic and clinical impact. For example, midazolam clearance decreases by 70%, while immunosuppressant and theophylline concentrations increase three-fold and two-fold with intensive care unit admission and infection. Cytochrome P450 activity appears to return to baseline level when the disease is resolved.
Studies that have assessed the impact of inflammation on CYP activity are lacking in pediatrics, yet it is a major factor to consider to improve drug efficacy or safety. The scarce current data show that the impact of inflammation is isoform and age dependent. An effort must be made to improve the understanding of the impact of inflammation on CYP activities in children to better individualize treatment.
细胞色素 P450(CYP)是参与药物在肝脏代谢的主要酶。儿科患者的治疗方案需个体化,不仅要考虑遗传、环境和生理因素,还要考虑个体发育。已发表的成人数据表明,炎症对 CYP 活性具有同工酶特异性影响,本研究旨在评估其在儿科人群中的影响。
本系统评价纳入了截至 2021 年 1 月 7 日在 PubMed 上发表的研究炎症对儿科 CYP 活性影响的文章。提取了炎症来源、受试药物(涉及的 CYP)、药物-疾病相互作用的影响、受试者数量和年龄以及研究设计等信息。
共纳入 27 项研究和病例报告。炎症对 CYP 活性的影响似乎与年龄和同工酶特异性相关,一些药物-疾病相互作用具有显著的药代动力学和临床影响。例如,入住重症监护病房和感染会使咪达唑仑清除率降低 70%,同时使免疫抑制剂和茶碱浓度增加 3 倍和 2 倍。当疾病得到解决时,CYP 活性似乎恢复到基线水平。
儿科中缺乏评估炎症对 CYP 活性影响的研究,但这是提高药物疗效或安全性的一个重要考虑因素。目前有限的数据表明,炎症的影响与同工酶和年龄有关。必须努力提高对炎症对儿童 CYP 活性影响的认识,以更好地实现个体化治疗。